LONDON – Nanomedicine specialist Midatech Ltd. closed a £6.3 million (US$9.7 million) funding round as it confirmed the formal launch of its joint venture with MonoSol Rx, in which the two partners will develop a gold nanoparticle-based formulation of insulin, designed to be delivered via a patch that adheres to the inside of the mouth.